RE:RE:RE:RE:RE:Keytruda resistance shown as a monotherapy in anal cancerAnother approval for Keytruda further opens the door for ONCY's pelareorep in combination with immune checkpoint inhibitors.
June 18, 2024 - Merck & Co.’s Keytruda has received the FDA’s green light for use in combination with chemotherapy, followed by the PD-1 inhibitor as a single agent, in patients with primary advanced or recurrent endometrial cancer, the company said Monday.
News of Keytruda’s latest approval came on the same day of an AstraZeneca announcement that its PD-L1 inhibitor Imfinzi has also secured an FDA approval in first-line dMMR endometrial cancer as part of a combination with chemo.
https://www.fiercepharma.com/pharma/mercks-keytruda-snags-40th-us-indication-leaps-ahead-gsk-broad-endometrial-cancer-approval